Market Eyes LiveZimmer Biomet Holdings, Inc. (ZBH) Stock Rating & Analysis
MELANY's data-driven read on Zimmer Biomet Holdings, Inc. · Orthopedic, Prosthetic & Surgical Appliances & Supplies.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants along with supplies and surgical equipment for orthopedic surgery. Following its acquisitions of Centerpulse (2003) and Biomet (2015), it holds the leading reconstructive market share in the US, Europe, and Japan. About two-thirds of revenue comes from large joints and about a fourth from extremities, trauma, sports medicine, and related products. It spun off its dental and spine businesses in 2022.
Why ZBH scores 65/100
MELANY scores Zimmer Biomet Holdings, Inc. 65/100 by weighing eight factors. Here is how ZBH breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 10.8x, earnings growth accelerating
- PEG ratio 0.67 (< 1 = undervalued)
- FCF yield 5.8%
Margins, returns on capital, and balance-sheet strength.
- Gross margin 70%
Direction and relative strength of the recent share-price trend.
- Price +7.2% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for ZBH
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Zimmer Biomet Holdings, Inc. sits in the Healthcare sector theme, which MELANY currently rates 26/100 for strength. Theme strength feeds ZBH's momentum and catalyst factors above.
ZBH trade plan (members only)
MELANY has a full position plan for Zimmer Biomet Holdings, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates ZBH
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Zimmer Biomet Holdings, Inc.'s 65/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about ZBH
Is Zimmer Biomet Holdings, Inc. (ZBH) a buy?
As of 2026-08-17, MELANY rated Zimmer Biomet Holdings, Inc. Favorable with a composite score of 65/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Zimmer Biomet Holdings, Inc.'s MELANY score?
Zimmer Biomet Holdings, Inc. (ZBH) has a MELANY composite score of 65/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the ZBH stock rating calculated?
MELANY scores ZBH from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Zimmer Biomet Holdings, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Zimmer Biomet Holdings, Inc. (ZBH) Favorable with a composite of 65/100 as of 2026-08-17. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the ZBH stock price forecast?
MELANY does not publish price targets or forecasts for ZBH. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 65/100 across eight factors for Zimmer Biomet Holdings, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is ZBH stock overvalued or undervalued?
MELANY's valuation factor currently reads 77/100 for Zimmer Biomet Holdings, Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives ZBH's read.
What price should I buy ZBH at?
Rather than chasing the current price, MELANY computes a smart entry zone for ZBH: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying ZBH stock?
The top risks MELANY currently flags for Zimmer Biomet Holdings, Inc.: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Zimmer Biomet Holdings, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 63/100 for Zimmer Biomet Holdings, Inc., and earnings track record, at 77/100. The 65/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will ZBH stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 59/100 for ZBH right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this ZBH rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-17. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores ZBH continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
ZBH's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.